PREDiCT: Tumour Models London 2020 (**FREE Passes Available)

Memo

Advancing In-vivo and emerging 3D/ex-vivo platforms, for comprehensive study of efficacy, safety, and immune response. This year, the PREDiCT: 9th Tumour Models London will unite Preclinical and Translational Oncology Scientists to fast-track oncology therapeutics into clinic through enhanced model platforms and selection strategy. In recent times, we have seen the uptake of new preclinical models that boost our understanding of immuno-oncology therapies, as well as emerging 3D platforms for more comprehensive study of target validation and immune response. Reflecting these developments, our 2020 Case Studies Include: - Roche discusses what we need for next gen model to enhance predictability and targeting?- Genmab shares compares Humanized Models for the Study of T-Cell Engaging Bispecifics in Vivo- GSK improves the safety predictability of IO modalities with Organ On Chip (OoC) models- Dana Faber Cancer institute reveals RNA-sequencing analysis of immunotherapy response in organotypic tumor spheroids- Institute of Cancer Research shares the Imaging of PD-L1 in head and neck cancer in response to oncolytic virotherapy URLs:Tickets: https://go.evvnt.com/670835-0?pid=5569Brochure: https://go.evvnt.com/670835-3?pid=5569 Price:General Admission: GBP 0.00 Speakers: Danilo Maddalo Head of Laboratory Roche, Nicola Ferrari Research Associate, Translational R and D Astex Pharmaceuticals, Pelin Candarlioglu Investigator, Complex In Vitro Models GSK, Frank Schwobel Associate Director, Preclinical Pharmacology and Toxicology Immatics, Gabriela Kramer- Marek Team Leader, Preclinical Molecular Imaging Institute of Cancer Research, Peter Boross Associate Director Genmab Date and Time: On Tuesday December 01, 2020 at 8:00 am (ends Thursday December 03, 2020 at 4:00 pm)